Join to View Full Profile
20 York StNew Haven, CT 06510
Phone+1 203-200-4822
Fax+1 203-200-2099
Dr. Deshpande is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Hari Deshpande is an oncologist based in New Haven, CT, with subspecialties in endocrine cancer, genitourinary oncology, head and neck cancer, and sarcoma. His medical training includes an internship, residency, and fellowship at Jacobi Medical Center/Albert Einstein College of Medicine, following his graduation from the University of Leeds School of Medicine in 1991. Dr. Deshpande has experience in neuro-oncology and various types of cancer such as squamous cell cancer of the bladder, thyroid, and parathyroid cancers. He has contributed to medical literature with publications in prominent journals like The New England Journal of Medicine and Cancer. His clinical trial involvement includes research on treatments for head and neck squamous cell carcinoma and desmoid tumors. Dr. Deshpande has received recognition, including the David Fischer Teaching Award from Yale Cancer Center.
Education & Training
Jacobi Medical Center/Albert Einstein College of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998- Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1993 - 1995
- Jacobi Medical Center/Albert Einstein College of MedicineInternship, Internal Medicine, 1992 - 1993
University of Leeds School of MedicineClass of 1991
Certifications & Licensure
CT State Medical License 2001 - 2027
NV State Medical License 2000 - 2003
NY State Medical License 2001 - 2003
AZ State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma Start of enrollment: 2007 Mar 01
- Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers Start of enrollment: 2007 May 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Publications & Presentations
PubMed
- Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.Alice P Chen, Christina L Rosenberger, Nancy Moore, Jared C Foster, Abdul Rafeh Naqash
Journal of Clinical Oncology. 2026-04-18 - 1 citationsTwenty-five years without progress: The enduring challenge of soft tissue sarcomas.Nicole J Hardy, Khaoula Ben Haj Frej, Rachel Nkansah, Kelly Olino, Hari Deshpande
Cancer. 2025-06-01 - 3 citationsUse of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.Hao Wu, Madina Sukhanova, Haiming Tang, Xinyan Lu, Minghao Zhong
Archives of Pathology & Laboratory Medicine. 2025-05-01
Press Mentions
Yale Cancer Center Shares Five Things You Need to Know About Sarcoma, a Rare CancerJuly 7th, 2021- New Haven Company's 'Orphan Drug' May Aid Fight Against Rare CancerFebruary 8th, 2021
- Connecticut Gets Slight Boost in Vaccine Supply, but Distributors Say They Need More DosesJanuary 28th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
